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Abstract
Background: Recent studies have demonstrated that pathological analysis of retroperitoneal residual masses of
patients with testicular germ cell tumors revealed findings of necrotic debris or fibrosis in up to 50% of patients. We
aimed at pursuing a clinical and pathological review of patients undergoing post chemotherapy retroperitoneal
lymph node dissection (PC-RPLND) in order to identify variables that may help predict necrosis in the
retroperitoneum.
Methods: We performed a retrospective analysis of all patients who underwent PC-RPLND at the University
Hospital of the University of São Paulo and Cancer Institute of Sao Paulo between January 2005 and September
2011. Clinical and pathological data were obtained and consisted basically of: measures of retroperitoneal masses,
histology of the orchiectomy specimen, serum tumor marker and retroperitoneal nodal size before and after
chemotherapy.
Results: We gathered a total of 32 patients with a mean age of 29.7; pathological analysis in our series
demonstrated that 15 (47%) had necrosis in residual retroperitoneal masses, 15 had teratoma (47%) and 2 (6.4%)
had viable germ cell tumors (GCT). The mean size of the retroperitoneal mass was 4.94 cm in our sample, without a
difference between the groups (P= 0.176). From all studied variables, relative changes in retroperitoneal lymph
node size (P= 0.04), the absence of teratoma in the orchiectomy specimen (P= 0.03) and the presence of
choriocarcinoma in the testicular analysis after orchiectomy (P= 0.03) were statistically significant predictors of the
presence of necrosis. A reduction level of 35% was therefore suggested to be the best cutoff for predicting the
absence of tumor in the retroperitoneum with a sensitivity of 73.3% and specificity of 82.4%.
Conclusions: Even though retroperitoneal lymph node dissection remains the gold standard for patients with
residual masses, those without teratoma in the primary tumor and a shrinkage of 35% or more in retroperitoneal
mass have a considerably smaller chance of having viable GCT or teratoma in the retroperitoneum and a
surveillance program could be considered.
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Background
Testicular cancer has become one of the most curable
solid neoplasms and serves as a paradigm for the multi-
modal treatment of malignancies. The appropriate inte-
gration of chemotherapy, retroperitoneal lymph node
dissection (RPLND) and observation for the manage-
ment of testis cancer has resulted in overall survival
rates greater than 90% [1,2].
RPLND plays an important role in the management of
patients with testicular germ cell tumors (GCTs), espe-
cially in those with residual masses after chemotherapy
[3]. To date, series have demonstrated that pathological
analysis of these masses reveals findings of necrotic deb-
ris or fibrosis in 40% to 50% of patients, teratoma in
35% to 40% and viable malignant cells in 10% to 15% of
patients [4].
Even though early recognition and resection of tera-
toma in the retroperitoneum after chemotherapy have
been accompanied by excellent prognosis, once it was
initially thought to represent a benign course when
present in the retroperitoneal space, but the untreated
disease may have a lethal potential due to progressive
local growth or malignant transformation, not to
mention its classical unresponsiveness to conventional
cisplatin-based chemotherapy regimens [3-6]. As for re-
sidual viable GCT, the consequence of its incomplete re-
section is certain disease progression [7]. Therefore, a
more aggressive approach should always be considered
when treating patients with teratoma or viable GCT in
the retroperitoneum [7,8].
Thus, the appropriate approach to residual masses fol-
lowing chemotherapy remains a controversial issue,
since the literature has shown that as many as half of
resected masses are basically composed of necrosis or fi-
brotic tissue and any sort of adjuvant therapy could be
waived [9]. In order to avoid a great number of ap-
parently unnecessary post-chemotherapy RPLND (PC-
RPLND), many studies have tried to develop algorithms
to predict the presence of necrosis in the retroperito-
neum. However, currently predictive models and im-
aging modalities cannot reliably predict the pathological
finding of necrosis/fibrosis at PC-RPLND [9].
Some authors have established that patients without
teratoma in the primary tumor and a shrinkage of 90%
or more in retroperitoneal mass had little chance of hav-
ing viable GCT or teratoma and could be safely put
under a surveillance program with periodic imaging
scans [10]. However, prospective analyses have demon-
strated that approximately 30% of patients will harbor
teratoma or viable malignancy even with normal post-
chemotherapy computed tomography (CT) results and
no teratoma in the primary tumor [9].
The purpose of this work is to pursue a clinical and
pathological review of patients undergoing PC-RPLND at
a reference university oncology center in Brazil, in order
to identify variables that may help predict the histological
finding of necrosis in the retroperitoneum and perhaps es-
tablish a differentiated surveillance protocol.
Methods
We performed a retrospective analysis of all patients
from our computerized database who underwent PC-
RPLND at our service between January 2005 and May
2011. Patients were operated on after having undergone
three to four cycles of primary chemotherapy with bleo-
mycin, etoposide and cisplatin.
Clinical and pathological data were obtained and con-
sisted basically of measures of retroperitoneal masses,
serum tumor markers, histology of the orchiectomy spe-
cimen, tumor marker values and retroperitoneal nodal
size before and after chemotherapy.
The presence of either immature or mature teratoma
in the resected specimen, as well as teratoma with ma-
lignant transformation, was considered part of the same
group. Choriocarcinoma, yolk sac tumors, embryonal
carcinoma and seminoma were considered viable GCTs.
All histological findings were submitted to quantitative
and qualitative analysis.
Post-chemotherapy alpha-fetoprotein (AFP) and lac-
tate dehydrogenase (LDH) levels were registered as a
continuous variable while human chorionic gonado-
tropin (hCG) levels were considered a categorical vari-
able ranging from undetectable to detectable when
serum concentrations were greater than 3 mIU.
Retroperitoneal nodal size before and after chemother-
apy was determined by the longest transverse diameter of
the largest mass on CT imaging. Relative change in nodal
size before and after chemotherapy was calculated by div-
iding post-chemotherapy nodal size by pre-chemotherapy
nodal size and was analyzed as a continuous variable.
Multiple variables were analyzed independently in
order to establish any predictive value for finding nec-
rotic tissue in the retroperitoneum. Statistical analysis
was performed using the Statistical Package for Social
Sciences (SPSS, version 12.0, Chicago, IL, USA), apply-
ing the Mann–Whitney U test for non-parametric vari-
ables and the Fisher's exact test for categorical variables,
with the level of significance set at P < 0.05.
A cut-off level for predicting necrosis at retroperitoneal
residual mass analysis was sought by constructing a receiver
operating characteristic (ROC) curve of all significant vari-
ables, which were generated using graphical visualization in
our statistical software. This study was carried-out in ac-
cordance with the Ethics Committee regulations.
Results and discussion
We gathered information on a total of 32 patients, who
were 18- to 49-years old (mean age 30.5) and harbored
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seminomatous, nonseminomatous or mixed tumors in
the testis tissue in different clinical stages. Three patients
(9.4%) had seminoma, five (16%) had pure nonseminoma
(choriocarcinoma, yolk sac tumors, embryonal carcin-
oma, teratoma, teratocarcinoma) and 24 (75%) harbored
mixed nonseminomatous GCT (NSGCT). None of the
patients with seminoma had normal AFP levels, indicat-
ing that these patients may have had tumors with similar
biological behavior to those with NSGCT.
At diagnosis, seven (22%) patients were classified as
having a stage I disease, while 21 (66%) were stage II
and four (12.5%) were stage III. Clinical stage I patients
were individuals with longer follow-up, who presented
with retroperitoneal disease nonresponsive to chemo-
therapy and ultimately underwent PC-RPLND.
Pathological analysis in our series demonstrated that
15 (47%) patients had necrosis in residual retroperiton-
eal masses, 15 had teratoma (47%) and two (6%) had vi-
able GCT: one seminoma and one yolk sac tumor. For
statistical reasons and in alignment with the aims of this
study, we divided those patients into two groups, assem-
bling patients with viable GCT and teratoma and analyz-
ing them as one group. Mean size of the retroperitoneal
mass was 4.94 cm in our sample, 3.79 cm in the group
of necrosis and 5.96 cm in the group of teratoma and vi-
able GCT (P= 0.176). There was also no difference be-
tween groups regarding stratification of nodal size, as
shown in Table 1.
Primary tumor histology revealed embryonal cell car-
cinoma in 56%, seminomatous elements in 16%, yolk sac
tumor in 19% and teratomatous elements in 56% of the
patients. Of the 18 patients with teratomatous elements
in the primary tumor, 13 (72%) had teratoma in the ret-
roperitoneum at PC-RPLND. Even in the absence of
teratoma in the primary tumor, teratoma was present in
the retroperitoneum in five patients (16%).
When comparing pathological analysis of primary tumor
specimens, we found a statistical difference when compar-
ing the prevalence of teratoma and choriocarcinoma.
Other findings, such as the presence of seminoma, yolk
sac tumor, embryonal carcinoma, endodermal sinus tumor
lymph vascular invasion (LVI), rete testis invasion and
spermatic invasion were similar between groups.
Univariate analysis of quantitative components at
orchiectomy histology, retroperitoneal node size with its
relative measures and serum markers are shown in
Table 2.
Even though the presence of teratoma in the primary
tumor was an important negative predictor for the find-
ing of necrosis, the quantitative analysis has proven to
be statistically irrelevant.
While relative reduction in mass size after chemother-
apy has been shown to be an important predictor of ne-
crosis, even when considering patients not responding
to chemotherapy, absolute reduction and enlargement of
the residual mass did not show a significant difference
between groups.
There was a statistical difference in AFP levels between
groups; however, when comparing relative changes in AFP
levels after chemotherapy, no difference was found. Com-
parison of LDH levels and their relative changes was
Table 1 Distribution according to nodal size in men
undergoing PC-RPLND
Necrosis Teratoma or
Viable GCT
Total P
Value
Number of patients (%) 15 (47) 17 (53) 32
Mean size (cm) 3.79 5.96 4.94 0.176
Node size number (%)
1 cm or less 1 (7) 1 (6) 2 (6) 0.514
1 to 2 cm 3 (20.0) 0 (0.0) 3 (10) 0.091
2to 5 cm 8 (53) 9 (53) 17 (53) 0.630
Greater than 5 cm 3 (20.0) 7 (41) 10 (31) 0.182
Data are shown as number (%). GCT, germ cell tumor; PC-RPLND, post-
chemotherapy retroperitoneal lymph node dissection.
Table 2 Univariate analysis predicting necrosis at PC-
RPLND
Necrosis Teratoma or
viable GCT
P
Value
Components at orchiectomy
histology (%):
Embryonal 22.7 ± 30.1 32.9 ± 29.7 0.370
Yolk sac 4.3 ± 11.5 4.1 ± 8.0 0.737
Teratoma 12.7 ± 23.7 13.8 ± 17.1 0.502
Endodermal sinus 1.7 ± 4.5 5.0 ± 11.7 0.628
Retroperitonial node size
RP node cm before chemotherapy 6.5 ± 4.1 6.1 ± 5.5 0.849
RP node cm after chemotherapy 3.2 ± 1.8 5.3 ± 4.8 0.331
Relative change in RP node size 31.9 ± 48.3 9.4 ± 38.8 0.044
Absolute change in RP node size 3.2 ± 2.9 0.78 ± 2.9 0.053
Relative reduction in RP node 56.4 ± 14.0 26.2 ± 20.1 <0.001
Relative enlargement in RP node 35.6 ± 44.1 60.1 ± 22.5 0.425
Serum markers
hCG after chemotherapy 0.0 0.0 **
AFP after chemotherapy 1.3 ± 0.4 22.1 ± 49.3 <0.001
Relative change in AFP after
chemotherapy
15.7 ± 46.7 −83.7 ± 5.13 0.075
LDH after chemotherapy 307.7 ± 60.7 324.0 ± 65.8 0.399
Relative change in LDH after
chemotherapy
1.5 ± 15.9 0.68 ± 27.4 0.915
** unable to calculate. Data expressed as mean± standard deviation. AFP,
alpha-fetoprotein; GCT, germ cell tumor; hCG, human chorionic gonadotropin;
LDH, lactate dehydrogenase; PC-RPLND, post-chemotherapy retroperitoneal
lymph node dissection; RP, retroperitoneal.
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nonsignificant. We were unable to compare hCG levels
between groups because we only had two patients whose
hCG levels were not undetectable.
Of all the studied variables, relative changes in retroperi-
toneal lymph node size (P =0.04), the absence of teratoma
in the orchiectomy specimen (P =0.03) and the presence
of choriocarcinoma in the testicular analysis after orch-
iectomy (P =0.03) were statistically significant predictors
of the presence of necrosis in the retroperitoneum.
ROC curves were built for variables that were inde-
pendent predictors of necrosis at PC-RPLND. Even
though the size of the retroperitoneal mass after chemo-
therapy showed no statistical difference, we also built a
curve for it. The variable relative reduction after chemo-
therapy was the only one with predictive value according
to the Youlden index. An area under the curve (AUC) of
0.710 was obtained and a reduction level of 35% was
therefore suggested to be the best cutoff for predicting
the absence of tumor in the retroperitoneum with a
sensitivity of 73% and a specificity of 82%. ROC curves
of isolated size of retroperitoneal mass, absence of tera-
toma and presence of choriocarcinoma did not indicate
significant findings.
In our institution, relative change in retroperitoneal
node size, absence of teratoma in the orchiectomy speci-
men and the presence of choriocarcinoma in the testicular
analysis after orchiectomy were statistically significant pre-
dictors of the presence of necrosis in the retroperitoneum
and a surveillance program could be considered, given the
uncertainty in predicting the histology of residual masses
after chemotherapy in patients with metastatic testicular
tumors.
Analysis of residual retroperitoneal masses after chemo-
therapy is being increasingly regarded as a fundamental
issue, not only for orienting adjuvant therapies, but also
because it has prognostic implications [11]. Outcome
assessments in patients with NSGCT have demonstrated
that incomplete resection of residual retroperitoneal
masses, the size of residual retroperitoneal masses and
the finding of teratoma and viable GCT at RPLND
independently predict disease progression and relapse
[11,12].
The size of residual retroperitoneal masses after
chemotherapy has traditionally been considered when
choosing the subsequent treatment modality [9]. Studies
have shown that residual masses smaller than 2 cm are
considered one of the most significant predictors for
finding necrosis at PC-RPLND at logistic regression [4].
Furthermore, a number of investigators continue to base
the decision to perform PC-RPLND on residual mass
size alone, obviating PC-RPLND in patients with re-
sidual masses of 1 cm or less [13].
However, recent studies have shown that after chemo-
therapy a third of retroperitoneal masses of <2 cm
harbored either teratoma or viable GCT [14]. Even
though we found a trend of having only necrosis in the
retroperitoneum for masses <2 cm (P= 0.09), in the
present study residual mass size alone has not appeared
to be a good predictor of necrosis, with nonsignificant
size differences between groups and an underrated AUC
in ROC curves. In addition, one case of teratoma in a
1 cm mass was registered in our sample. Therefore, we
advocate that the decision of not operating on patients
cannot be based on mass size alone due to the lack of
consensus in the literature [9,10,13,14].
Traditional series report necrotic debris or fibrosis in
40% to 50%, teratoma in 35% to 40% and viable malig-
nant cells in 10% to 15% of patients [3]. In more recent
analyses, the incidence of residual microscopic teratoma
in the retroperitoneum has decreased to approximately
20% to 25%, with an increase of necrotic tissue findings
of up to 60% and stable rates of viable GCT [15]. It has
been reported that an increase in the proportion of ne-
crosis is generally attributed to stage migration and the
use of more effective chemotherapy regimens, especially
in patients achieving a complete response to chemother-
apy [15].
In our series we found a distribution pattern similar to
former studies, with almost 50% of patients harboring
teratoma in the retroperitoneal histology at RPLND,
which may suggest that our chemotherapy regimens
have been having inferior rates of complete responders
or simply because our group is composed of patients in
more advanced stages.
Teratoma-negative primary tumor and volumetric re-
gression of at least 90% after chemotherapy have been
described as being highly predictive of harboring necro-
sis only at PC-RPLND [9,16]. Other series include nor-
mal serum tumor markers, and node size < 2 cm, the
presence of yolk sac tumor or embryonal carcinoma on
primary tumor and lymph vascular invasion, among
others [9,10,15-17]. On the other hand, some authors
have been unable to identify variables to be highly pre-
dictive of harboring necrosis only at PC-RPLND [15,18].
Nevertheless, currently predictive models fail to accur-
ately predict necrosis in the retroperitoneum, since al-
most 30% of patients will harbor teratoma or viable
malignancy even with normal post-chemotherapy CT
and no teratoma in the primary tumor [9]. A study car-
ried out at the Memorial Sloan-Kettering Cancer Center
revealed that 26% of patients had teratoma or viable
GCT, even those with radiographically normal retroperi-
toneum who underwent PC-RPLND [9].
The relatively small number of patients when com-
pared to other institutional retrospective studies is a
limitation of the present study; however, other studies
with similar sample sizes have also come to significant
findings.
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In the present study, relative changes in retroperiton-
eal node size stood out as the single best predictor of
the presence of necrosis in the retroperitoneum, which
is in accordance with actual logistic regression models
[9,10]. While other series suggest 90% as a shrinkage
cutoff value to reliably predict necrosis, our quantitative
analysis have demonstrated a cutoff level of 35% with
approximate sensitivity and specificity [9].
The absence of teratoma has also been demonstrated
to be significant in qualitative analysis, but not in quan-
titative analysis. The presence of choriocarcinoma in the
testicular histology predicted necrosis in the retroperito-
neum, despite only four (12.5%) patients who had such a
finding. This association is an interesting finding that
has not been previously reported. We reviewed the lit-
erature and no possible explanations were found. We
believe further investigation is necessary to confirm this
finding, since the number of patients in our sample is
relatively small.
Conclusions
Even though RPLND remains the gold standard for
patients with residual masses, those without teratoma in
the primary tumor and a shrinkage of 35% or more in
retroperitoneal mass have a considerably smaller chance of
having viable GCTs or teratoma in the retroperitoneum.
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